Consistency of Helicobacter pylori eradication rates of first-line concomitant and sequential therapies in Korea: A nationwide multicenter retrospective study for the last 10 years

Bong Eun Lee, Joon Sung Kim, Byung Wook Kim, Jie Hyun Kim, Jin Il Kim, Jun Won Chung, Seong Woo Jeon, Jeong Hoon Lee, Ji Hyun Kim, Nayoung Kim, Ju Yup Lee, Seung Young Seo, Seon Young Park, Sung Eun Kim, Moon Kyung Joo, Hyun Joo Song, Ki Bae Kim, Chang Seok Bang, Hyun Jin Kim

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Eradication rate of standard triple therapy for H. pylori has declined to unacceptable level, and alternative regimens such as concomitant and sequential therapy have been introduced. We aimed to assess the consistency of eradication rates of concomitant and sequential therapies as for the first-line H. pylori eradication in Korea. Methods: A nationwide multicenter retrospective study was conducted including 18 medical centers from January 2008 to December 2017. We included 3,800 adults who had test to confirm H. pylori eradication within 1 year after concomitant or sequential therapy. Results: Concomitant and sequential therapy were prescribed for 2508 and 1292 patients, respectively. The overall eradication rate of concomitant therapy was significantly higher than that of sequential therapy (91.8% vs. 86.1%, p <.001). In time trend analysis, the eradication rates of concomitant therapy were 90.2%, 88.2%, 92.1%, 94.3%, 91.1%, and 93.4% for each year from 2012 to 2017 with an increasing trend (p =.0146), while those of ST showed no significant trend (p =.0873). Among 263 patients with second-line therapy, bismuth quadruple therapy showed significantly higher eradication rate than quinolone-based triple therapy (73.9% vs. 51.5% in ITT analysis, p =.001; 82.7% vs. 63.0% in PP analysis, p =.002). Conclusion: Concomitant therapy is the best regimen for the first-line H. pylori eradication showing consistently higher eradication rate with an increasing trend for the last 10 years in Korea. Bismuth quadruple therapy should be considered for second-line therapy after eradication failure using non-bismuth quadruple therapy.

Original languageEnglish
Article numbere12780
JournalHelicobacter
Volume26
Issue number2
DOIs
StatePublished - Apr 2021

Keywords

  • Helicobacter pylori
  • concomitant therapy
  • sequential therapy
  • time trend analysis

Fingerprint Dive into the research topics of 'Consistency of Helicobacter pylori eradication rates of first-line concomitant and sequential therapies in Korea: A nationwide multicenter retrospective study for the last 10 years'. Together they form a unique fingerprint.

Cite this